Immune checkpoint inhibitors will represent 47% of the 5EU gastric and gastroesophageal market by 2029, says GlobalData
The lack of approved immune checkpoint inhibitors (ICI) in the gastric and gastroesophageal adenocarcinoma (G/GEJAC) market in the *5EU is expected to significantly enhance the revenue of Opdivo and Keytruda following their upcoming label expansions.
In fact, GlobalData’s latest report, ‘Gastric and Gastroesophageal Junction Adenocarcinoma Global Drug Forecast and Market Analysis to 2029’, notes that these expansions will also primarily drive growth across the wider 8MM* G/GEJAC market, however, the impact will be more apparent in the 5EU - given the lack of approved ICIs.
Miguel Ferreira, MSc, Oncology and Hematology Analyst at GlobalData, comments: “GlobalData expects that Keytruda will enter the 5EU markets first as a monotherapy, amassing $23m by its third year in the market. It will lose out to Opdivo’s $24m in its second year in the market - given Opdivo’s more in-demand approval for the adjuvant setting.”
Key opinion leaders (KOLs) interviewed by GlobalData stated that ICIs are of little interest to physicians as monotherapies or third-line options. Therefore, only combinatorial label expansions are expected to significantly impact the value of the market. Hence, Keytruda’s earlier entry won’t offer the usual first-to-market advantage.
Ferreira concludes: “Despite entering the 5EU market first in 2021, Keytruda will generate similar revenue to that of Tislelizumab in 2029, $138m verses $111m, respectively - despite the latter only being forecast to enter the market in 2024 Meanwhile, Opdivo will be the distinguished market leader with $303m.”
*8MM = The US, France, Germany, Italy, Spain, the UK, Japan and China
* 5EU = France, Germany, Italy, Spain and the UK
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 207 936 6400
Asia-Pacific: +91 40 6616 6809
For expert analysis on developments in your industry, please connect with us on:
Notes to Editors:
Quotes provided by Miguel Ferreira, MSc, Oncology and Hematology Analyst at GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.